Cognitive effects of pegylated interferon in individuals with primary brain tumors
- PMID: 19484406
- DOI: 10.1007/s11060-009-9920-6
Cognitive effects of pegylated interferon in individuals with primary brain tumors
Abstract
Cognitive changes associated with interferon treatment include impaired verbal memory, attention, processing speed, and executive functioning. Pegylated interferon is a relatively new, long-lasting form of interferon alpha, but data regarding its cognitive effects in brain tumor patients are limited. Participants in this study were 35 primary brain tumor patients who received pegylated interferon at tumor recurrence. A neuropsychological battery assessed verbal memory, executive functioning, attention, information processing speed, and language functioning. Individual growth curve analyses were used to estimate cognitive change throughout treatment with interferon. Results revealed performance declined on a task of psychomotor speed and upper extremity dexterity. Although decline in a few tests was found, its degree may have been reduced because individuals were tested after tumor recurrence where a substantial amount of cognitive change had already potentially occurred due to surgery, radiation therapy, and chemotherapy. Thus, participants may not have been starting at their baseline cognitive status and the potential neurotoxic effects of interferon may have been obscured by prior treatments. An alternative explanation, however, is that treatment with pegylated interferon did not produce further impairment and patients experienced stability in their cognitive functioning.
Similar articles
-
Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C.Hepatology. 2007 May;45(5):1154-63. doi: 10.1002/hep.21633. Hepatology. 2007. PMID: 17465000 Clinical Trial.
-
Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C.Am J Gastroenterol. 2010 Jul;105(7):1551-60. doi: 10.1038/ajg.2010.3. Epub 2010 Jan 26. Am J Gastroenterol. 2010. PMID: 20104219 Free PMC article. Clinical Trial.
-
Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.Cancer. 2008 Sep 15;113(6):1404-11. doi: 10.1002/cncr.23722. Cancer. 2008. PMID: 18615619 Clinical Trial.
-
Treatment of hepatitis B with interferon and combination therapy.Clin Liver Dis. 2004 May;8(2):353-70. doi: 10.1016/j.cld.2004.02.004. Clin Liver Dis. 2004. PMID: 15481344 Review.
-
Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon.J Hepatol. 2003;39 Suppl 1:S164-7. doi: 10.1016/s0168-8278(03)00329-5. J Hepatol. 2003. PMID: 14708697 Review. No abstract available.
Cited by
-
Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors.Adv Drug Deliv Rev. 2017 Sep 15;119:159-174. doi: 10.1016/j.addr.2017.06.011. Epub 2017 Jun 22. Adv Drug Deliv Rev. 2017. PMID: 28648712 Free PMC article. Review.
-
Nano to micro delivery systems: targeting angiogenesis in brain tumors.J Angiogenes Res. 2010 Oct 8;2(1):20. doi: 10.1186/2040-2384-2-20. J Angiogenes Res. 2010. PMID: 20932320 Free PMC article.
-
Cytokines: shifting the balance between glioma cells and tumor microenvironment after irradiation.J Cancer Res Clin Oncol. 2015 Apr;141(4):575-89. doi: 10.1007/s00432-014-1772-6. Epub 2014 Jul 9. J Cancer Res Clin Oncol. 2015. PMID: 25005789 Free PMC article. Review.
-
The impact of disease activity and interferon-α on the nervous system in systemic lupus erythematosus.Arthritis Res Ther. 2025 Mar 20;27(1):60. doi: 10.1186/s13075-025-03539-2. Arthritis Res Ther. 2025. PMID: 40114276 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical